Paolo Bonfanti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paolo Bonfanti has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Elena Ricci
Fondazione A.S.I.A. Onlus, Buccinasco, Milan, Italy
56 shared publications - Giuseppe Vittorio De Socio
Department of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06132 Perugia, Italy
36 shared publications - Antonio Di Biagio
University of Genoa
33 shared publications - Giordano Madeddu
Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy
30 shared publications Tiziana Quirino
Department of Infectious Diseases, Busto Arsizio Hospital, Piazzale Solaro 3, 21052 Busto Arsizio, Italy
24 shared publicationsCanio Martinelli
Infectious Diseases Unit, Careggi Hospital, Florence, Italy
20 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (11) , 1413
Intrapartum and Perinatal Outcomes in Pregnant Women Living with HIV: 17-Year Experience of Italian Referral Center
Advances in antiretroviral therapy (ART) have dramatically reduced the risk of mother-to-child transmission (MTCT) of HIV, leading to substantial changes in obstetric management. However, data describing the implementation of updated recommendations in routine clinical practice, particularly regarding mode of birth after a previous cesarean section (CS) and delayed cord clamping (DCC), remain limited. We aimed to evaluate temporal changes in intrapartum and postpartum management among women living with HIV (WLWH) over a 17-year period at a tertiary referral center. We conducted a retrospective cohort study including all WLWH who delivered at a university hospital between January 2009 and December 2025. Pregnancies were categorized into three periods according to major changes in national recommendations on mode of birth: 2009–2013, 2014–2018, and 2019–2025. Maternal HIV characteristics, ART, obstetric management, and delivery and neonatal outcomes were compared among study periods. Sixty-three women had 83 pregnancies during the study period. The proportion of women receiving ART at conception increased significantly over time (p < 0.001), paralleled by a shift toward contemporary antiretroviral regimens. At delivery, only three women had a viral load ≥50 copies/mL, all during the earliest study period. Planned pre-labor CS declined significantly (p < 0.001), whereas vaginal delivery increased, reaching 51.8% in 2019–2025, without any case of vertical HIV transmission. Among women with a previous CS managed after 2014, the acceptance rate of a trial of labor after CS (TOLAC) was 53.3%. All women declining TOLAC cited fear of HIV transmission despite viral suppression. DCC was performed in 89.4% of newborns, with no adverse neonatal outcomes attributable to the procedure. Contemporary multidisciplinary management of WLWH enables high rates of viral suppression, increasing use of vaginal birth, and implementation of DCC with no case of vertical transmission observed. Given the sample size and observational design, these findings are reassuring but not conclusive. Nevertheless, previous HIV-related cesarean delivery continues to influence women’s decisions regarding mode of birth in subsequent pregnancies, highlighting the need for individualized counseling to facilitate evidence-based shared decision-making.
- 13 November 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (11) , 1413
Open AccessIntrapartum and Perinatal Outcomes in Pregnant Women Living with HIV: 17-Year Experience of Italian Referral Center
Advances in antiretroviral therapy (ART) have dramatically reduced the risk of mother-to-child transmission (MTCT) of HIV, leading to substantial changes in obstetric management. However, data describing the implementation of updated recommendations in routine clinical practice, particularly regarding mode of birth after a previous cesarean section (CS) and delayed cord clamping (DCC), remain limited. We aimed to evaluate temporal changes in intrapartum and postpartum management among women living with HIV (WLWH) over a 17-year period at a tertiary referral center. We conducted a retrospective cohort study including all WLWH who delivered at a university hospital between January 2009 and December 2025. Pregnancies were categorized into three periods according to major changes in national recommendations on mode of birth: 2009–2013, 2014–2018, and 2019–2025. Maternal HIV characteristics, ART, obstetric management, and delivery and neonatal outcomes were compared among study periods. Sixty-three women had 83 pregnancies during the study period. The proportion of women receiving ART at conception increased significantly over time (p < 0.001), paralleled by a shift toward contemporary antiretroviral regimens. At delivery, only three women had a viral load ≥50 copies/mL, all during the earliest study period. Planned pre-labor CS declined significantly (p < 0.001), whereas vaginal delivery increased, reaching 51.8% in 2019–2025, without any case of vertical HIV transmission. Among women with a previous CS managed after 2014, the acceptance rate of a trial of labor after CS (TOLAC) was 53.3%. All women declining TOLAC cited fear of HIV transmission despite viral suppression. DCC was performed in 89.4% of newborns, with no adverse neonatal outcomes attributable to the procedure. Contemporary multidisciplinary management of WLWH enables high rates of viral suppression, increasing use of vaginal birth, and implementation of DCC with no case of vertical transmission observed. Given the sample size and observational design, these findings are reassuring but not conclusive. Nevertheless, previous HIV-related cesarean delivery continues to influence women’s decisions regarding mode of birth in subsequent pregnancies, highlighting the need for individualized counseling to facilitate evidence-based shared decision-making.
- 28 October 2026
- Published by Wiley in HIV Medicine
Weight, blood glucose and lipid changes in the course of long‐acting cabotegravir + rilpivirine: A prospective two‐year evaluation
Introduction: There are little real‐world data from observational cohorts regarding the impact of long‐acting (LA) cabotegravir (CAB) and rilpivirine (RPV) treatment on weight and blood lipids. Methods: This multicentre, prospective, observational study included people with human immunodeficiency virus initiating LA CAB+RPV within the Surveillance Cohort Long‐Term Toxicity Antiretrovirals (SCOLTA) cohort. Weight and cholesterol levels (total, high‐density lipoprotein cholesterol (HDL) and low‐density lipoprotein cholesterol (LDL)) were collected at six‐month intervals within two‐year follow‐ups. A multivariate mixed linear model was run to determine the association between change from baseline and participants' characteristics. Results: A total of 671 participants were enrolled, with a median follow‐up of 22 (interquartile range [IQR]: 13–29) months. The median age was 49 years (IQR 40–58) and median duration of antiretroviral therapy (ART) was 10.3 years (IQR 6.4–16.7). There was no significant change in mean weight after 1 year and 2 years, with differences of −0.25 kg (95% CI: −0.59 to +0.08, p = 0.14) and −0.18 kg (95% CI: −0.70 to +0.33, p = 0.48), respectively. The multivariable analysis revealed that weight change was significantly associated with baseline body mass index (BMI). People with obesity and overweight experienced a significantly greater reduction in weight, compared to those of normal weight (mean estimate −1.66 kg, 95% CI −2.69 to −0.64, and −0.72 kg, 95% CI: −1.24 to −0.19, respectively). Total cholesterol (+6 mg/dL, 95% CI: +1.4 to +10.7), HDL cholesterol (+2.9 mg/dL, 95% CI: +1.2 to +4.7) and LDL cholesterol (+2.4 mg/dL, 95% CI: −1.8 to +6.6) increased at 2 years, with no change in the total/HDL ratio. Conclusions: Body weight remained stable in the SCOLTA cohort after switching to LA CAB+RPV for 2 years. There was a modest but significant increase in cholesterol levels, though the ratio of total to HDL cholesterol remained stable.
- 28 October 2026
- Published by Wiley in HIV Medicine
Weight, blood glucose and lipid changes in the course of long‐acting cabotegravir + rilpivirine: A prospective two‐year evaluation
Introduction: There are little real‐world data from observational cohorts regarding the impact of long‐acting (LA) cabotegravir (CAB) and rilpivirine (RPV) treatment on weight and blood lipids. Methods: This multicentre, prospective, observational study included people with human immunodeficiency virus initiating LA CAB+RPV within the Surveillance Cohort Long‐Term Toxicity Antiretrovirals (SCOLTA) cohort. Weight and cholesterol levels (total, high‐density lipoprotein cholesterol (HDL) and low‐density lipoprotein cholesterol (LDL)) were collected at six‐month intervals within two‐year follow‐ups. A multivariate mixed linear model was run to determine the association between change from baseline and participants' characteristics. Results: A total of 671 participants were enrolled, with a median follow‐up of 22 (interquartile range [IQR]: 13–29) months. The median age was 49 years (IQR 40–58) and median duration of antiretroviral therapy (ART) was 10.3 years (IQR 6.4–16.7). There was no significant change in mean weight after 1 year and 2 years, with differences of −0.25 kg (95% CI: −0.59 to +0.08, p = 0.14) and −0.18 kg (95% CI: −0.70 to +0.33, p = 0.48), respectively. The multivariable analysis revealed that weight change was significantly associated with baseline body mass index (BMI). People with obesity and overweight experienced a significantly greater reduction in weight, compared to those of normal weight (mean estimate −1.66 kg, 95% CI −2.69 to −0.64, and −0.72 kg, 95% CI: −1.24 to −0.19, respectively). Total cholesterol (+6 mg/dL, 95% CI: +1.4 to +10.7), HDL cholesterol (+2.9 mg/dL, 95% CI: +1.2 to +4.7) and LDL cholesterol (+2.4 mg/dL, 95% CI: −1.8 to +6.6) increased at 2 years, with no change in the total/HDL ratio. Conclusions: Body weight remained stable in the SCOLTA cohort after switching to LA CAB+RPV for 2 years. There was a modest but significant increase in cholesterol levels, though the ratio of total to HDL cholesterol remained stable.
- Open Access
- 17 August 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (8) , 796
Real-World Antibiotic Strategies for Multidrug-Resistant Pseudomonas aeruginosa: Evidence from the Italian SUSANA Multicentre Study
Background/Objectives: Multidrug-resistant (MDR) Pseudomonas aeruginosa pneumonia and bloodstream infections (BSI) remain challenging because of their severity, limited therapeutic options, and high mortality, despite the availability of novel β-lactam-based agents. We aimed to describe real-world treatment patterns, characteristics associated with treatment and infusion-strategy selection, and the association of these strategies with clinical outcomes in the retrospective, multicentre Italian SUSANA cohort, an observational study evaluating the use, safety, and outcomes of novel antibiotics in hospitalized patients. Methods: Adults with MDR P. aeruginosa pneumonia and/or BSI treated with novel antipseudomonal agents for ≥72 h were included. Treatment was classified as monotherapy or combination therapy, and infusion strategy as prolonged/continuous or standard. The primary outcome was 28-day all-cause mortality. A multivariable Cox regression analysis was performed. Results: Among 173 patients, pneumonia was the most frequent clinical presentation (74.0%). Monotherapy was used in 111 patients (64.2%), combination therapy in 62 (35.8%), and prolonged/continuous infusion in 120 (69.4%). Ceftolozane–tazobactam (CT) (64.7%) and ceftazidime–avibactam (CZA) (20.2%) were the most prescribed agents. Patients receiving prolonged/continuous infusion, regardless of monotherapy or combination therapy, had greater baseline clinical severity than those receiving standard infusion. Overall, 28-day mortality was 23.7%. In the multivariable analysis, neither combination therapy nor prolonged/continuous infusion was independently associated with reduced mortality, whereas septic shock (aHR 4.10, 95% CI 1.01–16.66) and ICU admission (aHR 2.53, 95% CI 1.06–6.08) increased mortality risk. Conclusions: In this multicentre real-world cohort, treatment strategies for MDR P. aeruginosa pneumonia and BSI appeared to be influenced by baseline severity and patient-related factors. Mortality was more strongly associated with markers of severe illness, including ICU admission and septic shock. No independent association with improved survival was observed for combination therapy compared with monotherapy or for prolonged/continuous compared with standard infusion. These findings highlight the prognostic role of baseline clinical severity and support the need for prospective, randomized, pharmacokinetic/pharmacodynamic (PK/PD)-guided studies to identify patients who may benefit from these strategies.
- 17 August 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (8) , 796
Open AccessReal-World Antibiotic Strategies for Multidrug-Resistant Pseudomonas aeruginosa: Evidence from the Italian SUSANA Multicentre Study
Background/Objectives: Multidrug-resistant (MDR) Pseudomonas aeruginosa pneumonia and bloodstream infections (BSI) remain challenging because of their severity, limited therapeutic options, and high mortality, despite the availability of novel β-lactam-based agents. We aimed to describe real-world treatment patterns, characteristics associated with treatment and infusion-strategy selection, and the association of these strategies with clinical outcomes in the retrospective, multicentre Italian SUSANA cohort, an observational study evaluating the use, safety, and outcomes of novel antibiotics in hospitalized patients. Methods: Adults with MDR P. aeruginosa pneumonia and/or BSI treated with novel antipseudomonal agents for ≥72 h were included. Treatment was classified as monotherapy or combination therapy, and infusion strategy as prolonged/continuous or standard. The primary outcome was 28-day all-cause mortality. A multivariable Cox regression analysis was performed. Results: Among 173 patients, pneumonia was the most frequent clinical presentation (74.0%). Monotherapy was used in 111 patients (64.2%), combination therapy in 62 (35.8%), and prolonged/continuous infusion in 120 (69.4%). Ceftolozane–tazobactam (CT) (64.7%) and ceftazidime–avibactam (CZA) (20.2%) were the most prescribed agents. Patients receiving prolonged/continuous infusion, regardless of monotherapy or combination therapy, had greater baseline clinical severity than those receiving standard infusion. Overall, 28-day mortality was 23.7%. In the multivariable analysis, neither combination therapy nor prolonged/continuous infusion was independently associated with reduced mortality, whereas septic shock (aHR 4.10, 95% CI 1.01–16.66) and ICU admission (aHR 2.53, 95% CI 1.06–6.08) increased mortality risk. Conclusions: In this multicentre real-world cohort, treatment strategies for MDR P. aeruginosa pneumonia and BSI appeared to be influenced by baseline severity and patient-related factors. Mortality was more strongly associated with markers of severe illness, including ICU admission and septic shock. No independent association with improved survival was observed for combination therapy compared with monotherapy or for prolonged/continuous compared with standard infusion. These findings highlight the prognostic role of baseline clinical severity and support the need for prospective, randomized, pharmacokinetic/pharmacodynamic (PK/PD)-guided studies to identify patients who may benefit from these strategies.
- 21 April 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (5) , 446
Cognitive impairment in long-COVID: frequency, trajectories and risk factors in a cohort study from Italy
- 21 April 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (5) , 446
Cognitive impairment in long-COVID: frequency, trajectories and risk factors in a cohort study from Italy
- Open Access
- 4 March 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (4)
Urinary antigen–negative Legionella pneumonia in critically ill patients: value of systematic molecular testing for optimal antimicrobial therapy
- 4 March 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (4)
Open AccessUrinary antigen–negative Legionella pneumonia in critically ill patients: value of systematic molecular testing for optimal antimicrobial therapy
- Open Access
- 29 December 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 697
Hybrid, infection- and vaccination-induced protection against laboratory- confirmed SARS-CoV-2 infection in a European multi-centre prospective cohort of healthcare workers, 2021–2024
Healthcare workers (HCWs) face high occupational exposure to SARS-CoV-2 and are a priority group for vaccination. Both natural infection and vaccination
- 29 December 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 697
Open AccessHybrid, infection- and vaccination-induced protection against laboratory- confirmed SARS-CoV-2 infection in a European multi-centre prospective cohort of healthcare workers, 2021–2024
Healthcare workers (HCWs) face high occupational exposure to SARS-CoV-2 and are a priority group for vaccination. Both natural infection and vaccination
- 22 July 2025
- Published by Springer Nature in Internal and Emergency Medicine
- p. 1-15
Persistence of symptoms in long-COVID: follow-up trajectories of 30 symptoms in 755 patients from a national multicenter study from Italy
Aim of the study was to define the patterns and determinants of symptom persistence in Long-COVID. The study population was represented by a multicenter cohort of patients with persisting symptoms after SARS-CoV-2 infection. Data collection included demographics, comorbidities, characteristics of acute infection, vaccination, reinfection, plus 30 different symptoms. The associations between covariates and persistence were assessed in multivariable logistic regression models. The study evaluated, at a mean interval of 453 days from acute SARS-CoV-2 infection, symptom persistence in 755 patients who had Long-COVID symptoms at a mean interval of 223 days from COVID-19. At second evaluation, 423 (56.0%) patients still presented one or more symptoms and 332 (44.0%) were symptom free. In those who remained symptomatic, the mean number of symptoms significantly reduced between the two evaluations. Compared to the first evaluation, the overall mean symptom regression rate was 72%, with lower regression rates observed for dyspnea (53%), anxiety (54%) and sleep disturbances (55%). The risk of persistence was increased for female sex, higher BMI, hospitalization and stronger ventilatory support during acute disease, higher number of initial symptoms and particular comorbidities (anxiety, chronic pulmonary disease, asthma), and decreased with the increase of age and time from acute SARS-CoV-2 infection. Neither SARS-CoV-2 vaccination nor reinfection showed significant associations with persistence. In this case series, roughly half of the patients that were symptomatic 7 months after acute SARS-CoV-2 infection remained symptomatic after an additional 7 months. The pattern and predictors of persistence draw attention to certain particular risk factors and manifestations that tend to persist longer than others.
- 22 July 2025
- Published by Springer Nature in Internal and Emergency Medicine
- p. 1-15
Persistence of symptoms in long-COVID: follow-up trajectories of 30 symptoms in 755 patients from a national multicenter study from Italy
Aim of the study was to define the patterns and determinants of symptom persistence in Long-COVID. The study population was represented by a multicenter cohort of patients with persisting symptoms after SARS-CoV-2 infection. Data collection included demographics, comorbidities, characteristics of acute infection, vaccination, reinfection, plus 30 different symptoms. The associations between covariates and persistence were assessed in multivariable logistic regression models. The study evaluated, at a mean interval of 453 days from acute SARS-CoV-2 infection, symptom persistence in 755 patients who had Long-COVID symptoms at a mean interval of 223 days from COVID-19. At second evaluation, 423 (56.0%) patients still presented one or more symptoms and 332 (44.0%) were symptom free. In those who remained symptomatic, the mean number of symptoms significantly reduced between the two evaluations. Compared to the first evaluation, the overall mean symptom regression rate was 72%, with lower regression rates observed for dyspnea (53%), anxiety (54%) and sleep disturbances (55%). The risk of persistence was increased for female sex, higher BMI, hospitalization and stronger ventilatory support during acute disease, higher number of initial symptoms and particular comorbidities (anxiety, chronic pulmonary disease, asthma), and decreased with the increase of age and time from acute SARS-CoV-2 infection. Neither SARS-CoV-2 vaccination nor reinfection showed significant associations with persistence. In this case series, roughly half of the patients that were symptomatic 7 months after acute SARS-CoV-2 infection remained symptomatic after an additional 7 months. The pattern and predictors of persistence draw attention to certain particular risk factors and manifestations that tend to persist longer than others.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2025 (1) , 6863015
Aspergillus Endocarditis: A Rare but Serious Complication During Treatment With Ibrutinib
Background: Aspergillus endocarditis (AE) is a rare but life‐threatening form of infective endocarditis, accounting for only 0.2% of cases. Despite antifungal and surgical treatment, AE remains a major diagnostic and therapeutic challenge with high mortality rates. Ibrutinib, a Bruton’s tyrosine kinase inhibitor used in the treatment of chronic lymphocytic leukemia (CLL), has been associated with early‐onset invasive aspergillosis. However, no cases of AE have been documented in patients undergoing ibrutinib therapy to date. Case Presentation: A 71‐year‐old man with relapsed CLL on third‐line ibrutinib therapy and a history of arrhythmic cardiomyopathy requiring an implantable cardioverter‐defibrillator (ICD) presented with a six‐month history of fever, cough, and fatigue. On admission, a full‐body computed tomography scan revealed intestinal ischemia and multiple thrombotic occlusions involving the kidney, spleen, and iliac artery. Markedly elevated beta‐D‐glucan and serum galactomannan levels prompted empirical initiation of isavuconazole. Transthoracic echocardiography identified a large vegetation (2.5 × 4 cm) on the mitral valve with ICD lead involvement. Despite urgent surgical intervention—including ICD extraction and mitral valve replacement—the patient succumbed to complications. Intraoperative valve cultures grew Aspergillus fumigatus. Conclusions: This report underscores the severity of AE despite combined surgical and antifungal therapy. Given its high mortality rates, clinicians should maintain a high index of suspicion for AE, particularly in immunocompromised patients or those with a history of cardiac surgery or implanted cardiac devices. Early recognition and aggressive intervention remain essential to improving outcomes.
- 1 January 2025
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2025 (1) , 6863015
Open AccessAspergillus Endocarditis: A Rare but Serious Complication During Treatment With Ibrutinib
Background: Aspergillus endocarditis (AE) is a rare but life‐threatening form of infective endocarditis, accounting for only 0.2% of cases. Despite antifungal and surgical treatment, AE remains a major diagnostic and therapeutic challenge with high mortality rates. Ibrutinib, a Bruton’s tyrosine kinase inhibitor used in the treatment of chronic lymphocytic leukemia (CLL), has been associated with early‐onset invasive aspergillosis. However, no cases of AE have been documented in patients undergoing ibrutinib therapy to date. Case Presentation: A 71‐year‐old man with relapsed CLL on third‐line ibrutinib therapy and a history of arrhythmic cardiomyopathy requiring an implantable cardioverter‐defibrillator (ICD) presented with a six‐month history of fever, cough, and fatigue. On admission, a full‐body computed tomography scan revealed intestinal ischemia and multiple thrombotic occlusions involving the kidney, spleen, and iliac artery. Markedly elevated beta‐D‐glucan and serum galactomannan levels prompted empirical initiation of isavuconazole. Transthoracic echocardiography identified a large vegetation (2.5 × 4 cm) on the mitral valve with ICD lead involvement. Despite urgent surgical intervention—including ICD extraction and mitral valve replacement—the patient succumbed to complications. Intraoperative valve cultures grew Aspergillus fumigatus. Conclusions: This report underscores the severity of AE despite combined surgical and antifungal therapy. Given its high mortality rates, clinicians should maintain a high index of suspicion for AE, particularly in immunocompromised patients or those with a history of cardiac surgery or implanted cardiac devices. Early recognition and aggressive intervention remain essential to improving outcomes.
- Open Access
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort